Hyphens Pharma Partners with Louis Widmer for Cerapro® Expansion
Hyphens Pharma International Limited, known for its innovative approaches in pharmaceuticals and consumer healthcare, has made strides in enhancing skin health with its product, Cerapro® MED Skin Barrier Cream. This acclaimed cream has received approval in accordance with the European Medical Device Regulation, allowing it to address the needs of patients suffering from atopic dermatitis, a prevalent form of eczema affecting individuals of all ages.
Launch and Licensing of Cerapro®
Hyphens Pharma is set to target a product launch for Cerapro® MED in six European countries, specifically focusing on regions that include Switzerland, Austria, the Netherlands, and Belgium. Through a recent licensing agreement with Louis Widmer SA, a respected name in dermatological products since 1960, Hyphens Pharma will initiate a collaborative effort to expand the reach of this advanced skin care solution.
Collaboration Details
This strategic collaboration allows Louis Widmer to take the reins in commercializing and promoting the Cerapro® MED product. Hyphens Pharma will benefit from an upfront fee along with ongoing royalties from sales, creating a win-win partnership designed to maximize the impact of Cerapro® in the European market. This collaboration signifies both companies' commitment to advancing patient care by leveraging Louis Widmer's extensive market presence.
The Significance of Cerapro®
Cerapro® MED is not just another skin cream; it is a scientifically formulated solution that lowers skin pH and restores the skin barrier, which are critical components in the management of atopic dermatitis. This product's approval as a CE-marked medical device reinforces its credibility and efficacy for patients seeking relief from eczema symptoms.
Patient-Centric Approach
Through this partnership, both Hyphens Pharma and Louis Widmer are united in their vision to deliver effective treatment options based on scientific evidence. The collaboration aims to make Cerapro® readily available to dermatologists and pediatricians, ensuring patients receive the care they deserve. Mr. Lim See Wah, Chairman and CEO of Hyphens Pharma, expressed enthusiasm for the partnership, noting the potential to significantly improve patient outcomes in European markets.
About Hyphens Pharma International Limited
Hyphens Pharma International Limited stands as a leader in Singapore's specialty pharmaceutical and consumer healthcare sectors. With a comprehensive network extending into Malaysia, Vietnam, Indonesia, and the Philippines, the company focuses on providing high-quality health solutions. Their portfolio spans three key areas: Pharmaceuticals and Medical Aesthetics, Proprietary Brands, and Digital Platforms including E-Pharmacy. This integrated approach supports the delivery of essential healthcare products across various regions.
Diverse Product Offerings
The Group specializes in developing and commercializing its proprietary dermatological products alongside exclusive partnerships with global brands. Their innovative ecosystem, which encompasses a medical hypermart and digital pharmacy platform, raises the standard for healthcare service delivery by ensuring efficient prescription fulfillment and direct medication delivery to patients.
About Louis Widmer SA
Louis Widmer SA, an esteemed Swiss company, is integral to the fields of cosmetics and pharmaceuticals. Since its establishment, the family-run business has prioritized sustainability and innovation in its mission to produce exceptional skin care products. Their expertise not only covers dermatological solutions for dry skin and acne but also extends to areas such as wound healing and anti-aging.
A Legacy of Quality
With a foundation built on high-quality dermatology products, Louis Widmer has become synonymous with trusted skin treatments that exhibit a commitment to enriching the lives of their customers. The company’s dedication to precision in development, production, and distribution distinguishes it as a leading player in the skincare industry.
Frequently Asked Questions
1. What is Cerapro® MED Skin Barrier Cream?
Cerapro® MED Skin Barrier Cream is a patented product designed to lower skin pH and restore the skin barrier, helping alleviate symptoms associated with atopic dermatitis.
2. When will Cerapro® be available in European markets?
The product launch is targeted for 2026 in six European markets including Switzerland, Austria, the Netherlands, and Belgium.
3. Who is involved in the commercialization of Cerapro®?
The commercialization will be handled by Louis Widmer SA, a well-respected company in the dermatological products sector.
4. What are the benefits of using Cerapro®?
The cream helps restore the skin barrier and lowers skin pH, supporting the skin's natural defenses against microbes and improving skin health.
5. What is Hyphens Pharma’s vision?
Hyphens Pharma aims to enhance the quality of healthcare through innovative products, expanding their reach in various international markets.
